Multiple primary malignancies in 788 Chinese patients with diffuse large B-cell lymphoma.
diffuse large B-cell lymphoma
incidence
multiple primary malignancies
prognosis
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
21
04
2023
received:
11
11
2022
accepted:
01
05
2023
medline:
21
7
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
ppublish
Résumé
Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of non-Hodgkin lymphoma worldwide. The emergence of multiple primary malignancies (MPMs) has been described as a new prognostic factor in many types of tumors. To investigate the morbidity, incidence, and survival of MPM in DLBCL, we retrospectively reviewed the characteristics of 788 patients with DLBCL. Forty-two patients were diagnosed with MPM, and 22 of them were diagnosed with subsequent primary malignancies (SPM) by pathologic biopsy. The incidence of SPM was associated with older age. Germinal center B-cell-like (GCB) subtype and earlier Ann Arbor stage DLBCL patients were more prone to SPM. MPM, age, lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group performance status (ECOG PS), Hans classification, and international prognostic index (IPI) score were prognostic risk factors for overall survival (OS). These data provide a comprehensive view of MPM in DLBCL. MPM was an independent prognostic factor of DLBCL in univariate analysis.
Sections du résumé
BACKGROUND
Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of non-Hodgkin lymphoma worldwide. The emergence of multiple primary malignancies (MPMs) has been described as a new prognostic factor in many types of tumors.
METHODS
To investigate the morbidity, incidence, and survival of MPM in DLBCL, we retrospectively reviewed the characteristics of 788 patients with DLBCL.
RESULTS
Forty-two patients were diagnosed with MPM, and 22 of them were diagnosed with subsequent primary malignancies (SPM) by pathologic biopsy. The incidence of SPM was associated with older age. Germinal center B-cell-like (GCB) subtype and earlier Ann Arbor stage DLBCL patients were more prone to SPM. MPM, age, lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group performance status (ECOG PS), Hans classification, and international prognostic index (IPI) score were prognostic risk factors for overall survival (OS).
CONCLUSION
These data provide a comprehensive view of MPM in DLBCL. MPM was an independent prognostic factor of DLBCL in univariate analysis.
Identifiants
pubmed: 37211902
doi: 10.1002/cam4.6070
pmc: PMC10358205
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14112-14119Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Haematologica. 2008 Sep;93(9):1335-42
pubmed: 18698083
Haematologica. 2006 Nov;91(11):1481-8
pubmed: 17043014
Cancer Med. 2021 Jul;10(13):4465-4477
pubmed: 34057285
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
Br J Haematol. 2017 Jul;178(1):72-80
pubmed: 28542862
J Clin Oncol. 2005 Nov 20;23(33):8447-52
pubmed: 16230674
Curr Opin Immunol. 2007 Apr;19(2):209-16
pubmed: 17276050
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Cancer. 2007 May 15;109(10):2077-82
pubmed: 17394190
J Clin Oncol. 2009 Feb 20;27(6):904-10
pubmed: 19114699
Cancer. 2016 Oct;122(19):3075-86
pubmed: 27377470
J Clin Oncol. 2011 May 10;29(14):1885-92
pubmed: 21483015
Blood Cancer J. 2018 Jan 25;8(1):1
pubmed: 29367648
Cancer Med. 2023 Jul;12(13):14112-14119
pubmed: 37211902
EJC Suppl. 2014 Jun;12(1):5-17
pubmed: 26217162
J BUON. 2011 Jan-Mar;16(1):112-5
pubmed: 21674860
Blood. 2004 Feb 15;103(4):1222-8
pubmed: 14576060
J Clin Oncol. 2005 Jun 20;23(18):4117-26
pubmed: 15867204
Br J Cancer. 2005 Aug 22;93(4):418-24
pubmed: 16106249
J Clin Oncol. 2005 Aug 1;23(22):5019-26
pubmed: 15983392
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
JAMA Oncol. 2017 Nov 01;3(11):1554-1557
pubmed: 28426850
J Natl Cancer Inst. 2018 Nov 1;110(11):1248-1258
pubmed: 29659938
J Clin Oncol. 2006 Apr 1;24(10):1582-9
pubmed: 16575009